BridgePoint Medical Inc. has raised $1 million from the sale of debt and stock warrants, according to documents filed with the Securities and Exchange Commission.
The company, based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
Last year, European regulators approved BridgePoint’s Chronic Total Occlusion (CTO) Crossing System comprised of the CrossBoss CTO Crossing Catheter and the Stingray CTO Re-Entry System. The company is currently conducting clinical trials in the United States.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Investors include Foundation Medical Partners, Polaris Ventures, New Enterprise Associates, and Mike Berman, a prominent local medical device enterpreneur.
Berman did not respond to an e-mail requesting comment.
